AbbVie   4Q Revenues: $5.1 billion (-2%)   4Q Earnings: $1.1 billion (-27%)   FY Revenues: $18.8 billion (+2%)   FY Earnings: $4.1 billion (-22%)   Comments: Global Humira sales increased 13% to $3.0 billion in the quarter. U.S. Humira sales grew 18% to $1.7 billion. Synagis sales were $314 million, down 6%. AndroGel sales were down 21% to $289 million. Kaletra sales were $228 million, down 9%. Lupron sales were $209 million, down 1%. Synthroid sales were up 13% to $189 million. Niaspan and TriC...